Angelini Pharma has acquired Catalyst Biosciences for $4.1 billion. This transaction marks a significant expansion for Angelini Pharma into the biopharmaceutical sector, specifically targeting rare disorders.
Catalyst Biosciences is a research and clinical development biopharmaceutical company dedicated to addressing unmet medical needs in rare disorders of the complement and coagulation systems. Its proprietary protease engineering platform has generated two late-stage clinical programs in hemophilia, a research program focused on engineering subcutaneous (SQ) complement inhibitors, and a discovery-stage Factor IX gene therapy construct, CB 2679d-GT, for Hemophilia B. The company also holds a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). Angelini Pharma, a pharmaceutical company, is expanding its therapeutic portfolio with this acquisition, signaling a strategic focus on specialized and innovative treatments.
This acquisition is strategically designed to integrate Catalyst's advanced protease engineering platform and its promising pipeline into Angelini Pharma's operations. The platform's ability to generate product candidates with improved functionality and potency, allowing for subcutaneous administration of recombinant coagulation factors and complement inhibitors, low-dose gene therapy constructs, and less frequently dosed intravitreal therapeutics, is a key asset. Synergies are expected from combining Angelini's established market presence and development infrastructure with Catalyst's innovative research and clinical assets. This union aims to accelerate the development and commercialization of novel therapies, particularly in rare blood and complement disorders.
The combined entity is now positioned to address critical unmet medical needs in rare disorders, particularly within hemophilia and complement-mediated conditions, leveraging a broader scientific and commercial foundation. This integration is expected to significantly strengthen Angelini Pharma's standing in the global biopharmaceutical landscape, fostering innovation and expanding its therapeutic offerings to patients worldwide.